{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:45:55Z","timestamp":1761821155109,"version":"3.41.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1023\/a:1026237730283","type":"journal-article","created":{"date-parts":[[2003,11,3]],"date-time":"2003-11-03T17:53:28Z","timestamp":1067882008000},"page":"127-130","source":"Crossref","is-referenced-by-count":11,"title":["Visual field defects in pediatric patients on vigabatrin monotherapy"],"prefix":"10.1007","volume":"107","author":[{"given":"Francisco J.","family":"Ascaso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Cristobal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5117119_CR1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314: 180-1.","journal-title":"Br Med J"},{"key":"5117119_CR2","first-page":"1693","volume":"314","author":"EA Wilson","year":"1997","unstructured":"Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. BrMed J 1997; 314: 1693.","journal-title":"BrMed J"},{"key":"5117119_CR3","first-page":"1693","volume":"314","author":"ICK Wong","year":"1997","unstructured":"Wong ICK, Mawer GE, Sanders JW. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent. Br Med J 1997; 314: 1693-4.","journal-title":"Br Med J"},{"key":"5117119_CR4","first-page":"1694","volume":"314","author":"N Blackwell","year":"1997","unstructured":"Blackwell N, Hayllar J, Kelly G. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. Br Med J 1997; 314: 1694.","journal-title":"Br Med J"},{"key":"5117119_CR5","first-page":"1694","volume":"314","author":"GFA. Harding","year":"1997","unstructured":"Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exixt. Br Med J 1997; 314: 1694.","journal-title":"Br Med J"},{"key":"5117119_CR6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7092.1455","volume":"314","author":"R Mackenzie","year":"1997","unstructured":"Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. Br Med J 1997; 314: 1693.","journal-title":"Br Med J"},{"key":"5117119_CR7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","volume":"50","author":"GL Krauss","year":"1998","unstructured":"Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-8.","journal-title":"Neurology"},{"issue":"Suppl8","key":"5117119_CR8","first-page":"179","volume":"38","author":"G Kramer","year":"1997","unstructured":"Kramer G, Scollo-Lavizzari G, Jallou P, et al. Vigabatrinassociated bilateral concentric visual field defects in four patients. Epilepsia 1997; 38(Suppl 8): 179.","journal-title":"Epilepsia"},{"key":"5117119_CR9","first-page":"817","volume":"116","author":"K Ruether","year":"1998","unstructured":"Ruether K, Pung T, Kellner V, Schmitz B, Hartman C, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field cotraction associated with vigabatrin. Arch Ophthalmol 1998; 116: 817-9.","journal-title":"Arch Ophthalmol"},{"key":"5117119_CR10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0013-4694(97)88397-X","volume":"103","author":"GFA Harding","year":"1997","unstructured":"Harding GFA, Wild JM, Robertson K, Edson A, Barber C, Lawden MC, Betts TA. Electroculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders. Electroencephalogr Clin Electrophysiol 1997; 103:96.","journal-title":"Electroencephalogr Clin Electrophysiol"},{"issue":"Suppl2","key":"5117119_CR11","first-page":"5","volume":"39","author":"R Kalviainen","year":"1998","unstructured":"Kalviainen R, Nousiainen I, Nikoskelainen E, et al. Visual field defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine therapy. Epilepsia 1998; 39(Suppl 2): 5.","journal-title":"Epilepsia"},{"key":"5117119_CR12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.52.6.1201","volume":"52","author":"CF Arndt","year":"1999","unstructured":"Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201.","journal-title":"Neurology"},{"key":"5117119_CR13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1212\/WNL.52.8.1537","volume":"52","author":"R Sankar","year":"1999","unstructured":"Sankar R, Wasterlain CG. Is the devil we know the lesser of two devils? Vigabatrin and visual fields. Neurology 1999; 52:1537.","journal-title":"Neurology"},{"key":"5117119_CR14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","volume":"67","author":"MC Lawden","year":"1999","unstructured":"Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716-22.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5117119_CR15","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","volume":"40","author":"JM Wild","year":"1999","unstructured":"Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784-94.","journal-title":"Epilepsia"},{"issue":"Suppl2","key":"5117119_CR16","first-page":"256","volume":"40","author":"T. Schmidt","year":"1999","unstructured":"Schmidt T. Constriction of the visual field in epilepsy patients taking vigabatrin and other antiepileptic drugs. Epilepsia 1999; 40 (Suppl 2): 256.","journal-title":"Epilepsia"},{"key":"5117119_CR17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","volume":"53","author":"R Kalviainen","year":"1999","unstructured":"Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen PS. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922-6.","journal-title":"Neurology"},{"key":"5117119_CR18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjo.84.5.499","volume":"84","author":"K Manucheheri","year":"2000","unstructured":"Manucheheri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000; 84: 499-505.","journal-title":"Br J Ophthalmol"},{"key":"5117119_CR19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(99)02095-4","volume":"354","author":"M Versino","year":"1999","unstructured":"Versino M, Veggioti P. Reversibility of vigabatrin-induced visual field defect. Lancet 1999; 354: 486.","journal-title":"Lancet"},{"key":"5117119_CR20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1212\/WNL.52.8.1713","volume":"52","author":"S Vanhatalo","year":"1999","unstructured":"Vanhatalo S, P\u00e4\u00e4kk\u00f6nen L. Visual field constriction in children treated with vigabatrin. Neurology 1999; 52: 1713.","journal-title":"Neurology"},{"key":"5117119_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2007-973477","volume":"30","author":"G Wohlrab","year":"1999","unstructured":"Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999; 30: 130-2.","journal-title":"Neuropediatrics"},{"key":"5117119_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/eye.2000.83","volume":"14","author":"IM Russell","year":"2000","unstructured":"Russell IM, Mackey DA, Taylor DS, Timms C, Walker JW. Vigabatrin-associated visual field defects in children. Eye 2000; 14: 334-9.","journal-title":"Eye"},{"key":"5117119_CR23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/1531-8249(200007)48:1<60::AID-ANA9>3.0.CO;2-E","volume":"48","author":"V Gross","year":"2000","unstructured":"Gross V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60-4.","journal-title":"Ann Neurol"},{"key":"5117119_CR24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/archopht.1989.01070010838024","volume":"107","author":"International Standardization Committee.","year":"1989","unstructured":"International Standardization Committee. Standard for Clinical Electroretinography. Arch Ophthalmol 1989; 107: 816-9.","journal-title":"Arch Ophthalmol"},{"key":"5117119_CR25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1469-8749.1988.tb04769.x","volume":"30","author":"J. Aicardi","year":"1988","unstructured":"Aicardi J. Clinical approach to the management of intractable epilepsy. Dev Med Child Neurol 1988; 30: 429-40.","journal-title":"Dev Med Child Neurol"},{"key":"5117119_CR26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1212\/WNL.44.7.1341","volume":"4","author":"JT Gilman","year":"1994","unstructured":"Gilman JT, Duchowny M, Jayakar P, et al. Medical intractability in children evaluated for epilepsy surgery. Neurology 1994; 4: 1341-3.","journal-title":"Neurology"},{"key":"5117119_CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.33588\/rn.27156.98111","volume":"27","author":"J. Aicardi","year":"1988","unstructured":"Aicardi J. El papel de los nuevos f\u00e1rmacos antiepil\u00e9pticos en las epilepsias infantiles. Rev Neurol 1988; 27: 301-5.","journal-title":"Rev Neurol"},{"issue":"suppl4","key":"5117119_CR28","first-page":"S973","volume":"39","author":"T Duchett","year":"1998","unstructured":"Duchett T, Brigell MG, Ruckh S. Electroretinographic changes are not associated with loss of visual function in pediatric epileptic patients following treatment with vigabatrin. Invest Ophthalmol Vis Sci 1998; 39 (suppl 4): S973.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5117119_CR29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.33588\/rn.2808.99015","volume":"28","author":"A Argumosa","year":"1999","unstructured":"Argumosa A, Herranz JL, Arteaga J, Barrasa J, Calles L, Armijo J. Vigabatrin and alterations of the visual field. Rev Neurol 1999; 28: 741-5.","journal-title":"Rev Neurol"},{"key":"5117119_CR30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.51.6.1779-a","volume":"51","author":"A Roubertie","year":"1998","unstructured":"Roubertie A, Bellet H, Echenne B. Vigabatrin-associated retinal cone system dysfunction. Neurology 1998; 51: 1779.","journal-title":"Neurology"},{"key":"5117119_CR31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000028707","volume":"29","author":"G Wohlrab","year":"1998","unstructured":"Wohlrab G, Boltshauser E, Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuro-pediatrics 1998; 29: 133-6.","journal-title":"Neuro-pediatrics"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026237730283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1026237730283\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026237730283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T04:09:11Z","timestamp":1753762151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1026237730283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["5117119"],"URL":"https:\/\/doi.org\/10.1023\/a:1026237730283","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"type":"print","value":"0012-4486"},{"type":"electronic","value":"1573-2622"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}